Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiMed BiologicsROCO:4147 -0.68%55 PS Ratio is 26.22 as of Jul. 21, 2026, which is 37% below its 10-year median of 41.34. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$86.15 (Significantly Undervalued). Among 930 Biotechnology companies, TaiMed Biologics ranks worse than 71.51% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TaiMed Biologics's share price is NT$58.50.
TaiMed Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.23. Hence, TaiMed Biologics's PS Ratio for today is 26.22.
The historical rank and industry rank for TaiMed Biologics's PS Ratio or its related term are showing as below:
ROCO:4147'
s PS Ratio Range Over the Past 10 Years
Min: 20.46 Med: 41.34 Max: 72119.17
Current: 26.22
During the past 13 years, TaiMed Biologics's highest PS Ratio was 72119.17. The lowest was 20.46. And the median was 41.34.
ROCO:4147's PS Ratio is ranked worse than 71.51% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs ROCO:4147: 26.22
During the past 12 months, the average Revenue per Share Growth Rate of TaiMed Biologics was -1.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -0.70% per year.
During the past 13 years, TaiMed Biologics's highest 3-Year average Revenue per Share Growth Rate was 600.90% per year. The lowest was -11.70% per year. And the median was 12.10% per year.
Back to Basics: PS Ratio
TaiMed Biologics (ROCO:4147) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
TaiMed Biologics PS Ratio Related Terms
TaiMed Biologics PS Ratio Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, TaiMed Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TaiMed Biologics's Share Price of today is NT$58.50. TaiMed Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TaiMed Biologics (ROCO:4147) has a PS Ratio of 26.22 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TaiMed Biologics and its competitors. This is 37% below median its historical median of 41.34. Over the past decade, TaiMed Biologics' PS Ratio has ranged from 20.46 to 72,119.17. According to the industry distribution chart, TaiMed Biologics ranks #665 out of 930 companies in the Biotechnology industry, placing it in the top 71.5%.
Is TaiMed Biologics' PS Ratio too high?
TaiMed Biologics' current PS Ratio of 26.22 is 37% below median its 10-year median of 41.34. Over the past 10 years, this metric has ranged from a low of 20.46 to a high of 72,119.17. The Biotechnology industry median PS Ratio is 9.30. TaiMed Biologics' value of 26.22 is 181.9% above this industry median. Based on the distribution chart, TaiMed Biologics ranks #665 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #665 out of 930 companies for PS Ratio. This places TaiMed Biologics in the lower half of its industry. The industry median PS Ratio is 9.30. TaiMed Biologics' value of 26.22 is 181.9% above this benchmark. Historically, TaiMed Biologics' own PS Ratio has ranged from 20.46 to 72,119.17 over the past decade. While the company's 10-year median is 41.34 vs. the industry median of 9.30, TaiMed Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current PS Ratio of 26.22 is 181.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current PS Ratio is 26.22, which is 37% below median its own 10-year median of 41.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.15, compared to a current price of NT$58.50 — trading 32.1% below its estimated fair value. The current PS Ratio is 26.22, which is 37% below median its 10-year median of 41.34 and 181.9% above the Biotechnology industry median of 9.30. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current PS Ratio is 26.22 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$58.50 is trading 32.1% below its estimated GF Value™ of NT$86.15.
GuruFocus considers TaiMed Biologics to be Significantly Undervalued.
Key valuation signals for ROCO:4147:
PS Ratio: 26.22 (37% below median its 10-year median of 41.34)
GF Value™: NT$86.15 vs. price of NT$58.50 (32.1% below fair value)
Industry Position: 181.9% above the Biotechnology median (#665 of 930)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
